|
시장보고서
상품코드
2039010
피부 편평세포암 치료 시장 : 치료법별, 용도별, 지역별Cutaneous Squamous Cell Carcinoma Treatment Market, By Treatment, By Application, By Geography |
||||||
피부 편평세포암 치료 시장은 2026년에 158억 달러로 추정되며, 2033년까지 258억 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 7.2%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 158억 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 7.20% | 2033년 시장 규모 예측: | 258억 달러 |
피부 편평세포암(cSCC)은 각질세포암, 즉 비흑색종 피부암으로 분류되는 일반적인 피부암의 일종입니다. 이는 피부, 머리카락, 손톱을 구성하는 단백질인 케라틴을 생성하는 표피 내 세포에서 유래합니다. 피부편평세포암(cSCC)은 침습성 질환으로 표피를 넘어 증식한 암세포를 말합니다. 자외선(UV)은 피부 편평세포암 발병의 주요 위험 요소입니다.
시장 역학
피부 편평세포암(cSCC)의 발생률 증가가 피부편평세포암 치료제 시장의 성장을 견인할 것으로 예상됩니다. 예를 들어, 미국 국립생물공학정보센터(NCBI)에 따르면 2020년 8월에 발표된 기사에 따르면 편평세포암은 기저세포암에 이어 미국에서 두 번째로 많은 피부암이라고 합니다. 또한, 미국에서는 매년 100만 건 이상의 편평세포암이 진단되는 것으로 보고되고 있습니다.
그러나 피부편평세포암(cSCC) 가이드라인의 표준화 부족으로 인해 의사들이 치료를 시행하는데 어려움을 겪고 있으며, 이는 시장 성장을 저해하는 요인으로 작용할 것으로 예상됩니다. 예를 들어, 미국 국립생물공학정보센터(NCBI)가 2020년 8월 발표한 논문에 따르면, 의사의 과제는 종양과 숙주의 특성에 따라 진행성 질환에 대한 환자의 위험을 적절히 평가하는 데 있다고 합니다.
본 조사의 주요 특징
- 이 보고서는 다양한 부문의 잠재적 수익 창출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신약 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 보고서는 회사 개요, 재무 실적, 제품 포트폴리오, 시장 입지, 유통 전략, 주요 개발, 전략 및 향후 계획과 같은 매개 변수를 기반으로 세계 피부 편평세포암 치료 시장의 주요 기업 프로파일을 작성합니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 의약품 출시, 약물군 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- '세계 피부 편평세포암 치료 시장' 보고서는 투자자, 공급업체, 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 피부 편평세포암 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 활용하여 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 피부 편평세포암 치료 시장 : 치료법별, 2021-2033년
제5장 세계의 피부 편평세포암 치료 시장 : 용도별, 2021-2033년
제6장 세계의 피부 편평세포암 치료 시장 : 지역별, 2021-2033년
제7장 경쟁 구도
제8장 섹션
KSMCutaneous Squamous Cell Carcinoma Treatment Market is estimated to be valued at USD 15,800 Mn in 2026 and is expected to reach USD 25,800 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 15,800 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.20% | 2033 Value Projection: | USD 25,800 Mn |
Cutaneous squamous cell carcinoma (cSCC) is a common type of skin cancer grouped in the class of keratinocyte cancer, or non-melanoma skin cancer. It is derived from cells within the epidermis that make keratin, the protein which makes up skin, hair, and nails. Cutaneous squamous cell carcinoma (cSCC) is an invasive disease, referring to cancer cells that have grown beyond the epidermis. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma.
Market Dynamics
Rising incidence of cutaneous squamous cell carcinoma (cSCC) is expected to drive cutaneous squamous-cell carcinoma treatment market growth. For instance, according to the National Center for Biotechnology Information (NCBI), an article published in August 2020, stated that squamous cell carcinoma is the second most common form of skin cancer in the U.S followed by basal cell carcinoma. It also reports that over one million squamous cell carcinoma cases are diagnosed in the U.S. each year.
However, lack of standardization in the guidelines for cutaneous squamous cell carcinoma (cSCC) creates a challenge for physicians to execute the treatment, and this is expected to hinder the market growth. For instance, according to the National Center for Biotechnology Information (NCBI), an article published in August 2020, stated that physician's challenge lies in properly assessing a patient's risk for aggressive disease based on tumor or host characteristics.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global cutaneous squamous-cell carcinoma treatment market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study are Eli Lilly and Company, Sanofi S.A., Cadila Healthcare Limited, Cipla Limited, Castle Biosciences, Regeneron Pharmaceuticals, Inc., Merck & Co., Inc., Vidac Pharma, LEO Pharma A/S, Regeneron Pharmaceuticals, Inc., Merck Sharp & Dohme, and Amgen Inc. among others
- Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
- The global cutaneous squamous-cell carcinoma treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cutaneous squamous-cell carcinoma treatment market.
Cutaneous Squamous Cell Carcinoma Treatment Market Segmentation
- By Treatment Insights
- Surgical
- Moh's Micrographic Surgery (MMS)
- Electrodessication or Curettage
- Non-surgical
- Chemotherapy
- Topical Immune Response Modifiers
- Radiotherapy
- Systemic Chemotherapy
- By Application Insights
- Hospitals
- Cancer Institutes
- Ambulatory Surgical Centers
- Others
- By Region Insights
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- Key Players in the Cutaneous Squamous Cell Carcinoma Treatment Market
- Eli Lilly and Company
- Sanofi S.A.
- Cadila Healthcare Limited
- Cipla Limited
- Castle Biosciences
- Regeneron Pharmaceuticals, Inc
- Merck & Co., Inc
- Vidac Pharma
- LEO Pharma A/S
- Merck Sharp & Dohme
- Amgen Inc
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Treatment
- Market Snippet, By Application
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Pipeline Analysis
- Reimbursement Scenario
- Epidemiology
- Pest Analysis
- Regulatory Scenario
- New Product Launches
- Collaborations and Agreements
- Market Trends
4. Global Cutaneous Squamous Cell Carcinoma Treatment Market, By Treatment, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Surgical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Moh's Micrographic Surgery (MMS)
- Electrodessication or Curettage
- Non-surgical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Chemotherapy
- Topical Immune Response Modifiers
- Radiotherapy
- Systemic Chemotherapy
5. Global Cutaneous Squamous Cell Carcinoma Treatment Market, By Application, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Cancer Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
6. Global Cutaneous Squamous Cell Carcinoma Treatment Market, By Region, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- North America
- Market Size and Forecast, By Treatment, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Treatment, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Treatment, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Treatment, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Treatment, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Treatment, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, (USD Mn)
- South Africa
- Central Africa
- North Africa
7. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sanofi S.A.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Cadila Healthcare Limited
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Cipla Limited
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Castle Biosciences
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Regeneron Pharmaceuticals, Inc
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Merck & Co., Inc
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Vidac Pharma
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- LEO Pharma A/S
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Regeneron Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Merck Sharp & Dohme
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Amgen Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Analyst Views
- Eli Lilly and Company
8. Section
- References
- Research Methodology
- About us and Sales Contact
